20.75
0.74 (3.70%)
| Previous Close | 20.01 |
| Open | 20.62 |
| Volume | 1,197,014 |
| Avg. Volume (3M) | 1,554,316 |
| Market Cap | 2,347,513,856 |
| Price / Sales | 252.07 |
| Price / Book | 3.57 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2026 |
| Operating Margin (TTM) | -1,525.50% |
| Diluted EPS (TTM) | -3.01 |
| Quarterly Revenue Growth (YOY) | 184.40% |
| Total Debt/Equity (MRQ) | 1.55% |
| Current Ratio (MRQ) | 10.49 |
| Operating Cash Flow (TTM) | -152.68 M |
| Levered Free Cash Flow (TTM) | -117.16 M |
| Return on Assets (TTM) | -33.54% |
| Return on Equity (TTM) | -69.21% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Immunome, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | 4.0 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.70 |
|
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 11.48% |
| % Held by Institutions | 83.28% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Enavate Sciences Gp, Llc | 31 Dec 2025 | 4,768,583 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 40.00 (HC Wainwright & Co., 92.77%) | Buy |
| Median | 33.50 (61.45%) | |
| Low | 30.00 (Stephens & Co., 44.58%) | Buy |
| Average | 34.25 (65.06%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 22.58 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Craig-Hallum | 04 Mar 2026 | 36.00 (73.49%) | Buy | 22.52 |
| Stephens & Co. | 04 Mar 2026 | 30.00 (44.58%) | Buy | 22.52 |
| HC Wainwright & Co. | 12 Feb 2026 | 40.00 (92.77%) | Buy | 22.44 |
| Wedbush | 15 Jan 2026 | 31.00 (49.40%) | Buy | 22.85 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BIENAIME JEAN JACQUES | 21.40 | - | 1,000 | 21,400 |
| Aggregate Net Quantity | 1,000 | |||
| Aggregate Net Value ($) | 21,400 | |||
| Aggregate Avg. Buy ($) | 21.40 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES | Director | 11 Mar 2026 | Buy (+) | 1,000 | 21.40 | 21,400 |
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 04 Feb 2026 | Announcement | Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 |
| 08 Jan 2026 | Announcement | Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 06 Jan 2026 | Announcement | Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |